ML339

Cat. No.:	HY-122197
CAS No.:	2579689-83-9
Molecular Formula:	$C_{26}H_{32}ClN_3O_5$
Molecular Weight:	502
Target:	CXCR; Apelin Receptor (APJ); Arrestin
Pathway:	GPCR/G Protein; Immunology/Inflammation
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 75 mg/mL (149.40 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.9920 mL	9.9602 mL	19.9203 mL
	5 mM	0.3984 mL	1.9920 mL	3.9841 mL
	10 mM	0.1992 mL	0.9960 mL	1.9920 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 3.75 mg/mL (7.47 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

ML339 is a selective CXCR6 antagonist with an IC_{50} of 140 nM. ML339 antagonizes β-arrestin recruitment and cAMP signaling pathway of human CXCR6 receptor induced by CXCL16, with IC_{50} of 0.3 μM and 1.4 μM, respectively. ML339 has no inhibitory effect on CXCR5、CXCR4、CXCR6 and apelin receptor (APJ), with IC_{50} >79 μM. ML339 has the potential to promote the development of prostate cancer research[1][2].

IC_{50} & Target

CXCR6
140 nM (IC_{50})

REFERENCES

[1]. Paul M Hershberger, et al. Probing the CXCR6/CXCL16 Axis: Targeting Prevention of Prostate Cancer Metastasis.

[2]. Peddibhotla S, et al. Discovery of small molecule antagonists of chemokine receptor CXCR6 that arrest tumor growth in SK-HEP-1 mouse xenografts as a model of hepatocellular carcinoma. Bioorg Med Chem Lett. 2020 Feb 15;30(4):126899.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA